RESEARCH LETTER

Phage therapy is highly effective against chronic lung infections with *Pseudomonas aeruginosa*

With an increase in cases of multidrug-resistant *Pseudomonas aeruginosa*, alternative and adjunct treatments are needed, leading to renewed interest in bacteriophage therapy. There have been few clinically relevant studies of phage therapy against chronic lung infections. Using a novel murine model that uses a natural respiratory inhalation route of infection, we show that phage therapy is an effective treatment against chronic *P. aeruginosa* lung infections. We also show efficacy against *P. aeruginosa* in a biofilm-associated cystic fibrosis lung-like environment. These studies demonstrate the potential for phage therapy in the treatment of established and recalcitrant chronic respiratory tract infections.

Chronic lung infections with *Pseudomonas aeruginosa*, associated with diseases such as cystic fibrosis (CF), non-CF bronchiectasis and COPD are often recalcitrant to treatment with antibiotics. With the rise of multidrug-resistant bacterial pathogens, there has been increased interest in the therapeutic potential of bacteriophages (phage) as an alternative or supplement to conventional antibiotics. Although progress has been made with the use of phage therapy against *P. aeruginosa* infections in chronic otitis and burn wounds, studies in chronic lung infections are restricted to a limited number of preclinical evaluations. Previous studies in animal models have demonstrated potential, but these have targeted short-term acute respiratory infections, or have involved very short time intervals between initial start of infection and therapeutic application. In addition, most models of chronic respiratory infection use agar beads impregnated with bacteria, which do not represent the natural infection process. Because of these limitations, previous studies were not designed to test phage efficacy against established chronic respiratory infections with *P. aeruginosa*.

We have recently developed a novel murine model of *P. aeruginosa* chronic lung infection that uses a natural respiratory inhalation route of infection. In this model, *P. aeruginosa* LESB65 (a representative of the most common clone of *P. aeruginosa* isolated from patients with CF in the UK, the Liverpool epidemic strain) adapts to its host niche in the nasopharynx, leading to migration and subsequent establishment in the lungs (as occurs in human chronic lung infection), and allows experiments to be conducted for much longer time periods (beyond 21–28 days). Infection is associated with the expression of biofilm-associated genes (as in CF), and ‘host-adapted’ bacteria recovered from the model are better able to establish lung infections when reintroduced to naïve mice. To provide a more stringent test of the potential of phage therapy in a clinically relevant model of chronic *P. aeruginosa* lung infection, we used a previously reported phage to challenge established populations of strain LESB65 (or the host-adapted derivative strain NP22_2), varying the length of time between establishment of initial infection and the application of the therapeutic agent.

The methodology associated with the murine model (using BALB/c mice 6–8 weeks old) has been described previously. The study was performed with the approval of, and in strict accordance with, the standards of the UK Home Office and the University of Liverpool Research Ethics Committee. Mice were infected intranasally with a fresh mid-log phase dose of 2 × 10⁶ colony-forming units (CFU) of *P. aeruginosa* in 50 μL phosphate-buffered saline (PBS). An amount of 2 × 10⁷ phage (phage PELP20) or PBS control was administered by the same route at indicated times. Mice were culled at predetermined times post infection by cervical dislocation. Lungs were collected, homogenised, serial-diluted and plated on *Pseudomonas*-selective plates (Oxoid, UK) to obtain CFU counts of bacteria recovered. Each experiment was repeated twice with five mice per group to give a total of ten per group per time point. Statistical analysis was performed using two-way ANOVA.

We first confirmed the efficacy of phage against strain LESB65 in an artificial sputum medium biofilm model developed to resemble the key physicochemical features of the lung of a patient with CF, including the presence of amino acids, mucin and extracellular DNA (figure 1). There was a 3-log reduction in *P. aeruginosa* CFU recovered from the phage-treated biofilm (after 24 hours), indicating that PELP20 can penetrate and kill bacteria within a biofilm-associated CF lung-like environment (figure 1).

In our initial murine model experiments, after infection of the mice with *P. aeruginosa* LESB65, phage were administered either (a) at 24 and 36 hours post infection, with bacterial CFUs counted at 48 hours (treatment 1) or (b) phage administration at 48 and 60 hours post infection, with bacterial CFUs counted at 72 hours (treatment 2). In both cases, complete clearance of *P. aeruginosa* from the lungs was achieved (figure 2). No reduction in CFUs was seen when ultraviolet-inactivated phage with no lytic activity was used (data not shown). We further extended the treatment gap between infection and application of phage to 6 days post infection, using the adapted LESB65-derived strain NP22_2, which readily establishes chronic infection in the murine lung. Here, the phage were administered at 144 hours (6 days) and 156 hours (6.5 days) post infection, with CFU counts at 168 hours (7 days) post infection (treatment 3). Phage therapy was again highly effective against the established 6-day lung infection, completely clearing bacteria from the lungs of 70% of mice, and significantly reducing CFU counts in the other 30% compared with controls (figure 2).

**Figure 1** Phage activity against *Pseudomonas aeruginosa* (LESB65 wild type (WT) and adapted strain NP22_2) in an artificial sputum medium (ASM) model. Phage PELP20 (1 × 10⁶ plaque-forming units) was administered 72 hours after establishment of *P. aeruginosa* mature biofilm in the ASM model; the figure shows colony-forming units (CFU)/mL at 24 hours post phage administration. Significant differences were determined using a two-way analysis of variance (**p < 0.01). Error bars indicate standard error of the mean SEM (n=6 biological replicates, mean values obtained from triplicate samples). There was no significant difference in fold reduction after phage treatment between LESB65 WT and NP22_2.
This is the first study reporting the efficacy of phage therapy up to 7 days post infection in a model where *P. aeruginosa* establishes a natural long-term chronic lung infection. Hence, we believe that it represents the sternest challenge yet for the efficacy of phage therapy in a respiratory infection model system. We show that phage administered intranasally up to 6 days after establishment of chronic lung infection were efficient in reducing bacterial numbers in the lungs of mice infected with *P. aeruginosa*, demonstrating the potential for phage therapy in the treatment of established and recalcitrant chronic respiratory tract infections. There are well-documented potential limitations with respect to phage therapy, in terms of host range, potential toxicity and the development of resistance. However, the key unanswered issue still remains, whether phage can gain access to and kill the bacteria in the spatially complex biofilm-associated mixed communities present in, for example, the CF lung. We have found that in a biofilm-associated murine model of chronic lung infection, and in an artificial sputum medium biofilm model, phage can effectively kill *P. aeruginosa*. While there is still more work to be done in developing phage cocktails with sufficient range, these data suggest that phage therapy could be an effective therapeutic approach against chronic respiratory infections, either alone against antibiotic-resistant bacteria or in combination with conventional antimicrobials.

Elaine M Waters,1 Daniel R Neill,1 Basak Kaman,1 Jaspreet S Sahota,2 Martha R J Clokie,2 Craig Winstanley,1 Aras Kadioglu1

1Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
2Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK

**Correspondence to** Professor Aras Kadioglu, Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, Ronald Ross Building, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK; A.Kadioglu@liv.ac.uk

CW and AK are co-senior authors

**Acknowledgements** The authors acknowledge Marina Godzhenzhiwla and Naina Chaniyishvi Eliava (Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia) for providing the phage mixture from which phage PELP20 was isolated.

**Contributors** EMW and DRN designed and performed the in vivo experiments. EMW, BK and JSS performed the in vitro experiments. EMW, DRN, MRJC, CW and AK analysed the data. EMW, CW and AK wrote the manuscript. CW and AK conceived, designed and supervised the study and contributed equally throughout.

**Funding** Institute of Infection and Global Health, University of Liverpool.

**Competing interests** None declared.

---

**REFERENCES**

Phage therapy is highly effective against chronic lung infections with *Pseudomonas aeruginosa*

Elaine M Waters, Daniel R Neill, Basak Kaman, Jaspreet S Sahota, Martha R J Clokie, Craig Winstanley and Aras Kadioglu

*Thorax* published online March 6, 2017

Updated information and services can be found at: [http://thorax.bmj.com/content/early/2017/03/06/thoraxjnl-2016-209265](http://thorax.bmj.com/content/early/2017/03/06/thoraxjnl-2016-209265)

**These include:**

**References**
This article cites 10 articles, 1 of which you can access for free at: [http://thorax.bmj.com/content/early/2017/03/06/thoraxjnl-2016-209265#BIBL](http://thorax.bmj.com/content/early/2017/03/06/thoraxjnl-2016-209265#BIBL)

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Open access (261)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)